Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
Source: SeekingAlpha
2026-03-10 00:47:58 ET
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile March 9, 2026 6:30 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
Telix Pharmaceuticals Limited
NASDAQ: TLX
TLX Trading
-4.28% G/L:
$7.61 Last:
97,515 Volume:
$7.74 Open:
TLX Latest News
February 27, 2026 07:00:00 am
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
February 26, 2026 05:35:00 am
1 Basically Unknown Stock That Could Turn Cancer?Imaging Breakthroughs Into Generational Wealth
TLX Stock Data
$2,423,405,271
305,469,565
N/A
8
N/A
Biotechnology & Life Sciences
Healthcare
US
Victoria
